Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (793) 793
Publication (49) 49
Book Review (12) 12
Book Chapter (7) 7
Conference Proceeding (2) 2
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cisplatin-based chemotherapy (695) 695
humans (595) 595
oncology (465) 465
index medicus (346) 346
chemotherapy (325) 325
male (305) 305
female (271) 271
cancer (256) 256
middle aged (224) 224
aged (215) 215
antineoplastic combined chemotherapy protocols - therapeutic use (209) 209
adult (187) 187
treatment outcome (140) 140
prognosis (130) 130
cisplatin - administration & dosage (128) 128
urology & nephrology (124) 124
bladder cancer (120) 120
neoplasm staging (100) 100
antineoplastic agents - therapeutic use (99) 99
phase-ii trial (96) 96
survival (95) 95
antineoplastic combined chemotherapy protocols - adverse effects (93) 93
care and treatment (93) 93
cisplatin (90) 90
urinary bladder neoplasms - drug therapy (85) 85
urothelial carcinoma (81) 81
retrospective studies (79) 79
testicular cancer (79) 79
risk factors (78) 78
transitional-cell carcinoma (77) 77
aged, 80 and over (76) 76
carcinoma (76) 76
urinary bladder neoplasms - pathology (76) 76
research (75) 75
antineoplastic agents - adverse effects (74) 74
combined modality therapy (73) 73
radical cystectomy (70) 70
gemcitabine (68) 68
pharmacology & pharmacy (67) 67
adjuvant chemotherapy (66) 66
carboplatin (65) 65
lung neoplasms - drug therapy (65) 65
cisplatin - therapeutic use (62) 62
radiotherapy (61) 61
survival analysis (61) 61
carcinoma, non-small-cell lung - drug therapy (60) 60
chemotherapy, adjuvant (59) 59
combination chemotherapy (58) 58
neoadjuvant chemotherapy (58) 58
urology (57) 57
metastasis (56) 56
phase-iii trial (56) 56
tumors (56) 56
analysis (55) 55
disease-free survival (55) 55
medicine & public health (53) 53
deoxycytidine - analogs & derivatives (52) 52
surgery (52) 52
survival rate (52) 52
quality-of-life (51) 51
testicular neoplasms - drug therapy (51) 51
drug therapy (50) 50
germ-cell tumors (50) 50
hematology, oncology and palliative medicine (50) 50
randomized-trial (50) 50
vinblastine (50) 50
carcinoma, transitional cell - drug therapy (49) 49
cooperative-oncology-group (49) 49
transitional-cell-carcinoma (49) 49
cisplatin - adverse effects (48) 48
adolescent (45) 45
antineoplastic agents - administration & dosage (45) 45
testicular neoplasms - therapy (45) 45
therapy (45) 45
toxicity (45) 45
antineoplastic combined chemotherapy protocols - administration & dosage (43) 43
deoxycytidine - administration & dosage (43) 43
high-dose chemotherapy (43) 43
cancer therapies (42) 42
double-blind (42) 42
health aspects (42) 42
carboplatin - administration & dosage (41) 41
cystectomy (41) 41
methotrexate (41) 41
neoplasms - drug therapy (41) 41
randomized controlled trials as topic (41) 41
neoadjuvant therapy (40) 40
ovarian neoplasms - drug therapy (40) 40
phase-iii (39) 39
hematology (38) 38
obstetrics & gynecology (38) 38
ovarian cancer (38) 38
follow-up studies (37) 37
gemcitabine plus cisplatin (37) 37
lymph-node dissection (37) 37
testicular neoplasms - pathology (36) 36
clinical trials as topic (35) 35
gynecologic-oncology-group (35) 35
neoplasm metastasis (35) 35
paclitaxel (35) 35
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (718) 718
German (27) 27
French (23) 23
Japanese (22) 22
Korean (2) 2
Spanish (2) 2
Chinese (1) 1
Hungarian (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Chemotherapy-induced peripheral neurotoxicity
by Cavaletti, Guido and Marmiroli, Paola
Nature Reviews Neurology, ISSN 1759-4758, 12/2010, Volume 6, Issue 12, pp. 657 - 666
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common, potentially severe and dose-limiting adverse effect of cancer treatment; however, the effects... 
CISPLATIN-BASED CHEMOTHERAPY | MICROTUBULE-STABILIZING AGENTS | PHASE-II TRIAL | OXALIPLATIN-INDUCED NEUROTOXICITY | ROOT GANGLION NEURONS | THALIDOMIDE-INDUCED NEUROPATHY | NON-HODGKINS-LYMPHOMA | PLACEBO-CONTROLLED TRIAL | OF-THE-LITERATURE | NERVE-FIBER DENSITY | CLINICAL NEUROLOGY | Peripheral Nervous System Diseases - therapy | Peripheral Nervous System Diseases - chemically induced | Antineoplastic Agents - adverse effects | Humans | Neoplasms - drug therapy | Drugs | Nervous system diseases | Chemotherapy | Diagnosis | Research | Health aspects | Risk factors | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy—Results From an International Study Group
by Karim Fizazi and Sergei Tjulandin and Roberto Salvioni and José R. Germà-Lluch and Jeannine Bouzy and David Ragan and Carsten Bokemeyer and Arthur Gerl and Aude Fléchon and Johann S. de Bono and Sally Stenning and Alan Horwich and Jörg Pont and Peter Albers and Ugo De Giorgi and Mark Bower and Anatoly Bulanov and Giorgio Pizzocaro and Jorge Aparicio and Craig R. Nichols and Christine Théodore and Jörg Thomas Hartmann and Hans-Joachim Schmoll and Stanley B. Kaye and Stéphane Culine and Jean-Pierre Droz and Cedric Mahé
Journal of Clinical Oncology, ISSN 0732-183X, 05/2001, Volume 19, Issue 10, pp. 2647 - 2657
Purpose: To assess the value of postsurgery chemotherapy in patients with disseminated nonseminomatous germ-cell tumors (NSGCTs) and viable residual disease... 
CISPLATIN-BASED CHEMOTHERAPY | RETROPERITONEAL MASS HISTOLOGY | POSTCHEMOTHERAPY SURGERY | OUTCOME ANALYSIS | ONCOLOGY | TERM FOLLOW-UP | TESTICULAR CANCER | RESIDUAL MASSES | ADJUNCTIVE SURGERY | MULTIVARIATE-ANALYSIS | IFOSFAMIDE SALVAGE THERAPY | Testicular Neoplasms - mortality | Prognosis | Humans | Male | Mediastinal Neoplasms - mortality | Testicular Neoplasms - pathology | Testicular Neoplasms - surgery | Retroperitoneal Neoplasms - mortality | Mediastinal Neoplasms - drug therapy | Multicenter Studies as Topic | Retroperitoneal Neoplasms - drug therapy | Adult | Retrospective Studies | Germinoma - surgery | Retroperitoneal Neoplasms - pathology | Retroperitoneal Neoplasms - surgery | Mediastinal Neoplasms - surgery | Germinoma - mortality | Germinoma - drug therapy | Combined Modality Therapy | Disease-Free Survival | Analysis of Variance | Germinoma - pathology | Testicular Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy
by Rapoport, Bernardo and Schwartzberg, Lee and Chasen, Martin and Powers, Dan and Arora, Sujata and Navari, Rudolph and Schnadig, Ian
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 57, pp. 23 - 30
Abstract Objective Rolapitant, a novel neurokinin-1 receptor antagonist (RA), was shown to protect against delayed chemotherapy-induced nausea and vomiting... 
Hematology, Oncology and Palliative Medicine | Multiple cycles | Rolapitant | Neurokinin-1 receptor antagonist | Antiemetic | Chemotherapy-induced nausea and vomiting | Subsequent cycles | DEXAMETHASONE | PHASE-III | APREPITANT | ORAL NK1 ANTAGONIST | CANCER | RECEPTOR ANTAGONIST | CISPLATIN-BASED CHEMOTHERAPY | PHARMACOKINETICS | ONCOLOGY | DOUBLE-BLIND | ANTIEMETICS PROVIDES PROTECTION | Granisetron - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Spiro Compounds - administration & dosage | Male | Spiro Compounds - adverse effects | Serotonin 5-HT3 Receptor Antagonists - administration & dosage | Young Adult | Clinical Trials, Phase III as Topic | Aged, 80 and over | Adult | Antiemetics - adverse effects | Female | Drug Therapy, Combination | Vomiting - prevention & control | Granisetron - adverse effects | Dexamethasone - administration & dosage | Neurokinin-1 Receptor Antagonists - adverse effects | Double-Blind Method | Administration, Oral | Ondansetron - administration & dosage | Neurokinin-1 Receptor Antagonists - administration & dosage | Treatment Outcome | Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Nausea - prevention & control | Retreatment | Vomiting - chemically induced | Aged | Ondansetron - adverse effects | Clinical Trials, Phase II as Topic | Prevention | Medical colleges | Chemotherapy | Nausea | Analysis | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Vascular Complications of Cancer Chemotherapy
by Cameron, Alan C., BSc(Hons), MB, ChB, MRCP and Touyz, Rhian M., MBBCh, PhD, FRCP, FRSE and Lang, Ninian N., BSc(Hons), MB, ChB, PhD, MRCP
Canadian Journal of Cardiology, ISSN 0828-282X, 2016, Volume 32, Issue 7, pp. 852 - 862
Abstract Development of new anticancer drugs has resulted in improved mortality rates and 5-year survival rates in patients with cancer. However, many of the... 
Cardiovascular | CISPLATIN-BASED CHEMOTHERAPY | LONG-TERM SURVIVORS | CARDIAC & CARDIOVASCULAR SYSTEMS | INDUCED CARDIOVASCULAR CHANGES | NITRIC-OXIDE | ANTI-ANGIOGENIC DRUGS | ARTERIAL OCCLUSIVE DISEASE | GROWTH-FACTOR INHIBITORS | RENAL-CELL CARCINOMA | BLOOD-PRESSURE | CHRONIC MYELOID-LEUKEMIA | Thrombosis - chemically induced | Vascular Endothelial Growth Factors - antagonists & inhibitors | Humans | Endothelium, Vascular - drug effects | Hypertension - drug therapy | Protein Kinase Inhibitors - adverse effects | Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Hypertension - chemically induced | Acute Kidney Injury - chemically induced | Cardiovascular Diseases - chemically induced | Platelet Activation - drug effects | Thrombosis - drug therapy | Index Medicus | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Pathophysiology of chemotherapy-induced peripheral neuropathy
by Starobova, Hana and Vetter, Irina
Frontiers in Molecular Neuroscience, ISSN 1662-5099, 05/2017, Volume 10, p. 174
Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several antineoplastics. It can lead to detrimental dose reductions and... 
Chemotherapy | Oxaliplatin | Pain | Paclitaxel | Neuropathy | Vincristine | Cisplatin | Cancer | paclitaxel | pain | vincristine | HIGH-DOSE PACLITAXEL | chemotherapy | DORSAL-ROOT GANGLION | OXALIPLATIN-RELATED NEUROTOXICITY | NEUROSCIENCES | ADVANCED COLORECTAL-CANCER | CISPLATIN-BASED CHEMOTHERAPY | ACUTE PAIN SYNDROME | RANDOMIZED PHASE-II | ACUTE LYMPHOBLASTIC-LEUKEMIA | neuropathy | oxaliplatin | cancer | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | cisplatin | Oxidative stress | Leukemia | Homeostasis | Mitochondrial DNA | Peripheral neuropathy | Epidemiology | Cancer therapies | Mitochondria | Cell growth | Metabolites | Autonomic nervous system | Cell cycle | Degeneration | Drug dosages | Deoxyribonucleic acid--DNA | Calcium homeostasis | Cell division | Inflammation | Gene expression | Quality of life | Axons | Cell death | Apoptosis | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study
by Hiura, Yuichiro and Takiguchi, Shuji and Yamamoto, Kazuyoshi and Takahashi, Tsuyoshi and Kurokawa, Yukinori and Yamasaki, Makoto and Nakajima, Kiyokazu and Miyata, Hiroshi and Fujiwara, Yoshiyuki and Mori, Masaki and Kangawa, Kenji and Doki, Yuichiro
Cancer, ISSN 0008-543X, 10/2012, Volume 118, Issue 19, pp. 4785 - 4794
Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor. This may cause cisplatin-induced gastrointestinal disorders and... 
cisplatin-based chemotherapy | ghrelin | appetite | esophageal cancer | food intake | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Ghrelin - administration & dosage | Prospective Studies | Nausea - chemically induced | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Esophageal Neoplasms - pathology | Patient Selection | Adult | Female | Surveys and Questionnaires | Vomiting - prevention & control | Ghrelin - therapeutic use | Appetite - drug effects | Treatment Outcome | Energy Intake - drug effects | Carcinoma, Squamous Cell - physiopathology | Nausea - prevention & control | Vomiting - chemically induced | Carcinoma, Squamous Cell - drug therapy | Neoadjuvant Therapy - methods | Cisplatin - adverse effects | Esophageal Neoplasms - physiopathology | Quality of Life | Aged | Neoplasm Staging | Esophageal Neoplasms - drug therapy | Chemotherapy | Usage | Care and treatment | Ghrelin | Research | Esophageal cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy
by Culp, Stephen H and Dickstein, Rian J and Grossman, H. Barton and Pretzsch, Shanna M and Porten, Sima and Daneshmand, Siamak and Cai, Jie and Groshen, Susan and Siefker-Radtke, Arlene and Millikan, Randall E and Czerniak, Bogdan and Navai, Neema and Wszolek, Matthew F and Kamat, Ashish M and Dinney, Colin P.N
Journal of Urology, The, ISSN 0022-5347, 2014, Volume 191, Issue 1, pp. 40 - 47
Purpose We evaluated the survival of patients with muscle invasive bladder cancer undergoing radical cystectomy without neoadjuvant chemotherapy to confirm the... 
Urology | cystectomy | urinary bladder neoplasms | outcomes assessment | risk | neoadjuvant therapy | SURVIVAL | UROTHELIAL CANCER | METAANALYSIS | STAGE | LYMPHOVASCULAR INVASION | CISPLATIN-BASED CHEMOTHERAPY | TRANSITIONAL-CELL-CARCINOMA | UROLOGY & NEPHROLOGY | EXPERIENCE | OUTCOMES | INVASIVE BLADDER-CANCER | Carcinoma, Transitional Cell - mortality | Urinary Bladder Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Urinary Bladder Neoplasms - drug therapy | Urinary Bladder Neoplasms - surgery | Patient Selection | Cystectomy | Carcinoma, Transitional Cell - pathology | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Urinary Bladder Neoplasms - pathology | Female | Neoadjuvant Therapy | Aged | Carcinoma, Transitional Cell - surgery | Neoplasm Staging | Adjuvant treatment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Personalized estimate of chemotherapy-induced nausea and vomiting: Development and external validation of a nomogram in cancer patients receiving highly/moderately emetogenic chemotherapy
by Hu, Zhihuang and Liang, Wenhua and Yang, Yunpeng and Keefe, Dorothy and Ma, Yuxiang and Zhao, Yuanyuan and Xue, Cong and Huang, Yan and Zhao, Hongyun and Chen, Likun and Chan, Alexandre and Zhang, Li
Medicine (United States), ISSN 0025-7974, 01/2016, Volume 95, Issue 2, p. e2476
Chemotherapy-induced nausea and vomiting (CINV) is presented in over 30% of cancer patients receiving highly/moderately emetogenic chemotherapy (HEC/MEC). The... 
CISPLATIN-BASED CHEMOTHERAPY | CINV | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | PREVENTION | APREPITANT | ASIA-PACIFIC COUNTRIES | EMESIS | ANTIEMETIC THERAPY | CLINICAL-PRACTICE | OF-CARE | Predictive Value of Tests | Age Distribution | Prognosis | Singapore | Nausea - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Nausea - epidemiology | Incidence | Young Adult | Antiemetics - therapeutic use | China | Nomograms | Adult | Female | Vomiting - prevention & control | Republic of Korea | Severity of Illness Index | Logistic Models | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Taiwan | Sex Distribution | Aged | Vomiting - epidemiology | Cohort Studies | Complications and side effects | Cancer patients | Care and treatment | Chemotherapy | Vomiting | Nausea | Risk factors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics
by Cavaletti, Guido, Prof and Alberti, Paola, MD and Marmiroli, Paola, MD
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 12, pp. 1151 - 1161
Summary Development of advanced and high-throughput methods to study variability in human genes means we can now use pharmacogenomic analysis not only to... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | CISPLATIN-BASED CHEMOTHERAPY | ONCOLOGY | ADVANCED GASTRIC-CANCER | CONTINUOUS VENOUS INFUSION | GLUTATHIONE-S-TRANSFERASE | PLACEBO-CONTROLLED TRIAL | VITAMIN-E SUPPLEMENTATION | OXALIPLATIN-BASED CHEMOTHERAPY | DRUG-METABOLIZING-ENZYMES | METASTATIC COLORECTAL-CANCER | Genetic Predisposition to Disease | Pharmacogenetics | Genetic Association Studies | Neurotoxicity Syndromes - genetics | Risk Assessment | Humans | Risk Factors | Genetic Markers | Patient Selection | Neurotoxicity Syndromes - etiology | Antineoplastic Agents - adverse effects | Peripheral Nervous System - drug effects | Precision Medicine | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer
by Meeks, Joshua J and Bellmunt, Joaquim and Bochner, Bernard H and Clarke, Noel W</